

Tobias Ozimkowski, Jessica Heckötter, Peter Maul, Caroline Angerer, Mareke Brüning, Katja Petry, Emiliano Melandri, and Andrzej Dzionek
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany

Introduction

It is established that CD8⁺ dendritic cells (DCs) in the mouse constitute a subpopulation that excels in cross-presentation. This cross-priming capacity of CD8⁺ DCs is essential for the initiation of effective cytotoxic T cell (CTL) responses against tumors. An equivalent subset of professional cross-priming DCs (XP-DCs) has recently been described in humans as lineage-negative, MHC class II^{high}, CD141 (BDCA3)⁺, XCR1⁺, CLEC9A⁺ DCs.¹⁻³ Here we demonstrate that XP-DCs that were isolated using a fully automated clinical-grade process are able to stimulate T cells in an antigen (Ag)-specific manner. To this end, isolated XP-DCs were loaded with antigens and activated with TLR3 agonist poly (I:C). Antigen-loaded, mature XP-DCs were then cocultured with autologous, antigen-specific T cells. Upon activation, XP-DCs up-regulated activation markers and produced a specific set of cytokines, including IFN- λ , a hallmark of XP-DCs.⁴ Furthermore, Ag-loaded XP-DCs efficiently presented antigens and stimulated T cells in an Ag-specific manner, resulting in proliferation of antigen-specific T cells and secretion of effector cytokines. Taken together, we developed the first clinical-scale process for the manufacture of next-generation XP-DC-based vaccines capable of stimulating antigen-specific CTL responses. This is now going to be used in two clinical studies.




Figure 1

Results

1 Performance of the ClinMACS Prodigy[®] CD141 (BDCA-3) Enrichment System

XP-DCs were enriched from leukapheresis samples by a two-step procedure consisting of pre-depletion of monocytes, B cells, and T cells and the subsequent positive selection of XP-DCs on the ClinMACS Prodigy (fig. 1). As a result of the pre-depletion process, the numbers of monocytes, T cells, and B cells were reduced by more than 10,000-fold (fig. 2A). The mean purity of XP-DCs in the final fraction amounted to 65%, when starting from leukapheresis

(LP) products with an average of 6.9×10^9 viable leukocytes and an XP-DC frequency of 0.08% (fig. 2B). The average XP-DC recovery was 46% (fig. 2C), which corresponded to a yield of 3.4×10^8 XP-DCs per 1×10^9 leukocytes in the LP sample (fig. 2D). The target cell fraction contained a residual 8% CD141^{low} pDCs and 10% CD141^{low} mDCs on average (not shown), resulting in a purity of CD141⁺ cells of 83% on average (fig. 2B; n = 22).




Figure 2

2 Activated XP-DCs produce a specific set of cytokines and show phenotypic characteristics of mature DCs

XP-DCs express high levels of TLR3 and respond to poly (I:C) stimulation by up-regulation of costimulatory molecules and production of large amounts of IFN- λ . To test their activation status upon TLR3 triggering, isolated XP-DCs were stimulated for 6 h or overnight in the presence or absence of poly (I:C) and analyzed by flow cytometry. Expression levels of some activation markers were already elevated in the absence of poly (I:C) while the levels of CCR7 and CD86 were additionally increased upon stimulation.

Overnight cultivation (17–19 h) further increased expression of all markers analyzed (fig. 3A; bar diagram; n = 3). In addition, cell culture supernatants were analyzed for cytokine secretion by ELISA or bead array (MACSPlex Cytokine 12 Kit, human). The stimulated cells secreted large amounts of IFN- λ , TNF- α , and IL-6 with fast kinetics upon TLR3 triggering, whereas non-stimulated DCs failed to secrete cytokines. Substantial amounts of IFN- α could also be detected, presumably due to residual pDCs (fig. 3B).




Figure 3

3 Peptide-loaded mature XP-DCs induce proliferation of antigen-specific T cells

The cross-presentation capability of activated CD141⁺ DCs was demonstrated by their capacity to re-stimulate autologous Ag-specific CD8⁺ T cells. To this end, XP-DCs were isolated from HLA-A2.1⁺ CMV-seropositive donors. To analyze Ag-specific stimulation, enriched XP-DCs were then incubated with pp65- and IE-1-derived peptide pools (MACS[®] GMP PepTivator[®] HCMV pp65 and PepTivator CMV IE-1) and simultaneously activated with poly (I:C) for 6 h. Activated and antigen-loaded XP-DCs were then cocultured with CellTrace[™] Dye-labeled autologous CD8⁺ T cells. Non-loaded XP-DCs were used as control. After ten days T cell proliferation was assessed based on cell numbers and the reduction of CellTrace Dye staining intensity. Additionally,

the specificity of T cell proliferation was analyzed by CMV pentamer staining; the analysis of T cell proliferation in the sample stimulated with non-loaded XP-DCs served as a control. T cells re-stimulated with XP-DCs loaded with pp65- and IE-1-derived peptide pools proliferated in an Ag-specific manner as shown by a 6-fold higher proliferation rate (fig. 4A) and reduced CellTrace Dye staining intensity (fig. 4B) compared to the sample with non-loaded XP-DCs. Furthermore, Ag specificity was shown by the increased frequency of pp65 peptide (NLVPMVATV)-specific and IE-1 peptide (VLAELVKQI)-specific CD8⁺ T cells detected by pentamer staining after stimulation with antigen-loaded XP-DCs (fig. 4B).




Figure 4

4 XP-DCs loaded with complete protein antigen are superior in inducing antigen-specific CTL responses

To show the antigen uptake and processing capacity of the XP-DCs, isolated cells from an HLA-A2.1⁺ CMV-seropositive donor were loaded overnight with pp65 protein or pp65-derived peptide pool and stimulated for 3 h with poly (I:C). Activated, antigen-loaded XP-DCs were then cocultured with CellTrace Dye-labeled autologous PBMCs. After ten days cells were stained with CellTrace Dye dilution and cell count. The Ag specificity of expanded T cells was further evaluated by re-stimulation with pp65- or MART-1-derived peptide pools and intracellular cytokine staining. T cells stimulated with pp65 protein-loaded

XP-DCs showed a seven times higher frequency of CD8⁺ T cells specific for the immunodominant pp65 peptide NLVPMVATV (fig. 5A) and also a higher proliferation rate (fig. 5B) compared to the sample with peptide pool-loaded XP-DCs. CD4⁺ T cells showed only a negligible proliferation rate (fig. 5A). Expanded T cells re-stimulated with pp65-derived peptide pool produced IFN- γ and TNF- α , but no IL-4. In contrast, re-stimulation with the irrelevant MART-1-derived peptide pool did not induce cytokine production (fig. 5C). These data demonstrate the capacity of isolated XP-DCs to take up, process, and cross-present antigens, and efficiently restimulate antigen-specific CD8⁺ memory T cells.




Figure 5

Conclusion

- The ClinMACS Prodigy CD141 (BDCA-3) Enrichment System enables fully automated production of XP-DC-based vaccines with high purity and recovery.
- Isolated XP-DCs acquire a mature phenotype and produce large amounts of IFN- λ upon TLR3 triggering.
- Activated and antigen-loaded XP-DCs efficiently induce proliferation and activation of antigen-specific T cells.

References

- Robbins, S.H. *et al.* (2008) *Genome Biol.* 9: R17.
- Poulin, L.F. *et al.* (2010) *J. Exp. Med.* 207: 1261–1271.
- Bachem, A. *et al.* (2012) *Front. Immunol.* 3: 214.
- Lauterbach, H. *et al.* (2010) *J. Exp. Med.* 207: 2703–2717.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS GMP Products are for research use only and ex vivo cell culture processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The ClinMACS[®] System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485. In the EU, the ClinMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The ClinMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The ClinMACS Reagents in combination with the ClinMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the ClinMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes, and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC (‘Human tissues and cells’), or the Directive 2002/98/EC (‘Human blood and blood components’) – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a ClinMACS System. In the US, the ClinMACS CD34 Reagent System, including the ClinMACS Plus Instrument, ClinMACS CD34 Reagent, ClinMACS PBS/EDTA Buffer, is FDA approved; all other products of the ClinMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). ClinMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. ClinMACS, ClinMACS Prodigy, MACS, the MACS logo, and PepTivator are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in various countries worldwide. All other trademarks mentioned in this document are the property of their respective owners and are used for identification purposes only. Copyright © 2017 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.